Genewity B.V.
Willem-Jan Krebber currently serves as Chief Operating Officer at Genewity B.V. since September 2024. Previously, Krebber held various leadership roles at ISA Pharmaceuticals from April 2010 to September 2024, including Chief Operating Officer, Director of Operations, and Senior Program Manager. Prior experience includes Associate Director of Program Management at Viroclinics Biosciences BV, Program Manager and Project Leader CMC at OctoPlus, Project Manager at Crucell, and Research Engineer at Centocor BV. Krebber holds a Master's degree in Biotech with a focus on Bioprocess Technology from Delft University of Technology and a Master's degree in Biology from Utrecht University. Recent education includes attendance at Nyenrode Business University from November 2022 to October 2023.
This person is not in any teams
This person is not in any offices
Genewity B.V.
Genewity B.V. is a recently founded biotech company based in Leiden, the Netherlands. Closely collaborating with the LUmc, we build on successes of our scientific and business teams in cell and gene therapies, including the first multi-centric clinical trial for gene therapy in the EU (the RAG1 SCID trial). Genewity has been founded to commercialize another potentially groundbreaking therapy for developing autologous thymus tissue de novo. Genewity is currently in a preclinical development stage and is engaged in raising a Series A to push the technology to the clinic.